A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas

Journal of Neuro-Oncology

Volumn 106, Issue 3, 2012, Pages 611-617

  Ruiz, Jimmy ^a   Case, Doug ^a   Enevold, Gina ^a   Rosdhal, Robin ^a   Tatter, Stephen B ^a   Ellis, Thomas L ^a   McQuellon, Richard P ^a   McMullen, Kevin P ^a   Stieber, Volker W ^b   Shaw, Edward G ^a   Lesser, Glenn J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b FORSYTH MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Clinical trial; Glioblastoma multiforme; High grade astrocytoma; Procarbazine; Thalidomide

Indexed keywords

PROCARBAZINE; THALIDOMIDE;

ADULT; APHASIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; MALE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISORDER; WEAKNESS;

ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; PROCARBAZINE; QUALITY OF LIFE; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 84857036020     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0698-y     Document Type: Article

References (37)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507
2. Central brain tumor registry of the United States (2004-2006) Statistical report: primary brain tumors in the United States
3. Wu W, Lamborn KR, Buckner JC et al (2010) Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol 12: 164-172
4. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466
5. Fine HA, Dear KBG, Loeffler JS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597 (Pubitemid 23100496)
6. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (9311): 1011-1018 (Pubitemid 34286538)
7. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiothearpy plus concomitant and adjuvant temozololmide for glioblastoma. N Engl J Med 352: 987-996 (Pubitemid 40349501)
8. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745
9. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740
10. Perry JR, Bélanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28 (12): 2051-2057
11. Singhal S, Mehta J, Eddlemon P et al (1998) Marked anti-tumor effect from anti-angiogenesis therapy with Thalidomide in high risk refractory multiple myeloma (Abst). Blood 92 (Suppl 1: (part 1 of 2)): 318a
12. Figg WD, Bergan R, Brawley O et al (1997) Randomized phase II study of thalidomide in androgen independent prostate cancer (Abst). Proc Am Soc Clin Oncol 16: 333a
13. Fine HA, Figg WD, Jaeckle K et al (2000) Phase II trial of antiangiogenic agent thalidomide in patients with recurrent highgrade gliomas. J Clin Oncol 18: 708-715 (Pubitemid 30106600)
14. Politi P, Reboredo G, Losso M et al (1998) Phase I trial of thalidomide in AIDS-related Kaposi Sarcoma (Abst). Proc Am Soc Clin Oncol 17: 41a
15. Glass J, Gruber ML, Nirenberg A (1999) Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme (Abst). Proc Am Soc Clin Oncol 18: 144a
16. Durie BGM, Stepan DE (1999) Efficacy of low dose thalidomide in multiple myeloma. VII international multiple myeloma workshop, Stockholm
17. Fine HA, Maher EA, Wen PY et al (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21 (12): 2305-2311
18. Chabner BA, Sponzi R, Hubbard S et al (1973) High-dose intermittent intravenous infusion of procarbazine. Cancer Chemother Rep 57: 361-363
19. Coyle T, Bushunow P, Winfield J et al (1992) Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. Cancer 69: 2523-2540
20. Lehmann DF, Hurteau TE, Newman N et al (1997) Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther 62: 225-229 (Pubitemid 27373471)
21. Newton HB, Bromberg J, Junck L et al (1986) Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J Neurooncol 15: 257-263
22. Rodriguez LA, Prados M, Silver P et al (1989) Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64: 2420-2423 (Pubitemid 20014920)
23. Newton HB, Junck L, Bronberg J et al (1990) Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40: 1743-1746 (Pubitemid 20383143)
24. Brandes AA, Ermani M, Turazzi S et al (1999) Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent highgrade gliomas: a phase II study. J Clin Oncol 17: 645-650 (Pubitemid 29075253)
25. Gundersen S, Lote K, Watne K (1998) A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. Eur J Cancer 34: 1565-1569 (Pubitemid 28446338)
26. Yung A, Albright R, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 (5): 588-593 (Pubitemid 30636298)
27. Grossman S, Carson KA, Batchelor TT et al (2006) The effect of enzyme inducing anti-seizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res 12: 5174-5181 (Pubitemid 44453346)
28. Macdonald D, Cascino T, Schold SJ et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280 (Pubitemid 20195640)
29. Cella DF, Tulsky DS, Gray G et al (1993) The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 11 (3): 570-579 (Pubitemid 23071057)
30. Marx GM, Pavlakis N, McCowatt S et al (2001) Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 54 (1): 31-38 (Pubitemid 33089257)
31. Shaw EG, Wang M, Coons S et al (2008) Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT ? procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J Clin Oncol 26 (May 20 suppl; abstr 2006)
32. Baumann F, Kollias SS et al (2004) Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 67 (1-2): 191-200 (Pubitemid 38418268)
33. Groves MD, Puduvalli VK, Chang SM et al (2007) A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81 (3): 271-277 (Pubitemid 46165331)
34. Puduvalli VK, Giglio P, Groves MD et al (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10 (2): 216-222
35. Fadul CE, Kingman LS, Meyer LP et al (2008) A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol 90 (2): 229-235
36. Chang SM, Lamborn KR, Malec M et al (2004) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60 (2): 353-357 (Pubitemid 39233451)
37. Fine HA, Kim L, Albert PS et al (2007) A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13 (23): 7101-7106 (Pubitemid 350276894)